Physician profile
Jong Mi Lee
NPI 1134356280
$173,685.59
in general payments reported to CMS, 2019-2025
18 companies · $26K in 2025
The $26K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $56K · 2022: $37K · 2023: $48K · 2024: $6,365 · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $30K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Travel and Lodging: $14K · Honoraria: $11K · Food and Beverage: $3,679 · Education: $60.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $30,122.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,721.00 |
| Travel and Lodging | $13,667.06 |
| Honoraria | $11,040.00 |
| Food and Beverage | $3,678.92 |
| Education | $60.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $58,598.14 | 2021-2025 | Vumerity, Tysabri, Tysabri |
| Alexion Pharmaceuticals, INC. | $25,083.04 | 2021-2025 | Soliris, Ultomiris |
| Genzyme Corporation | $23,070.95 | 2021-2025 | |
| Ani Pharmaceuticals, INC. | $9,786.11 | 2023 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $9,739.55 | 2021-2023 | Uplizna |
| Emd Serono, INC. | $9,724.19 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $8,160.17 | 2021-2024 | Zeposia |
| Celgene Corporation | $7,991.14 | 2021-2024 | Zeposia |
| Novartis Pharmaceuticals Corporation | $7,573.28 | 2021-2025 | |
| Amgen INC. | $6,178.66 | 2024-2025 | Uplizna |
| Novartis Pharma Ag | $2,549.50 | 2021-2023 | Kesimpta |
| Greenwich Biosciences, INC. | $1,600.00 | 2021 | |
| Mallinckrodt Hospital Products INC. | $1,517.48 | 2021-2022 | |
| Genentech USA, INC. | $1,469.98 | 2021 | |
| Tg Therapeutics, INC. | $420.68 | 2024-2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $127.89 | 2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $68.27 | 2021 | |
| Sandoz INC. | $26.56 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jong Mi Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.